NCT01722240View on ClinicalTrials.gov

Liraglutide in Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 1, 2012

Primary Completion Date

January 1, 2019

Study Completion Date

July 29, 2019

Conditions
Type 1 Diabetes
Interventions
DRUG

Liraglutide 1.8mg

DRUG

Placebo

Trial Locations (1)

14215

Diabetes-Endocrinology Center of WNY, Buffalo

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University at Buffalo

OTHER

NCT01722240 - Liraglutide in Type 1 Diabetes | Biotech Hunter | Biotech Hunter